Experienced in Ependymoma

Dr. Matthew C. Solhjem

Radiation Oncology
Providence
4805 Northeast Glisan Street, Garden Level, 
Portland, OR 
Accepting New Patients
Offers Telehealth
Experienced in Ependymoma
Providence
4805 Northeast Glisan Street, Garden Level, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Solhjem is a Radiation Oncologist in Portland, Oregon. Dr. Solhjem is rated as an Experienced provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Pleuropulmonary Blastoma, and Non-Muscle Invasive Bladder Cancer. Dr. Solhjem is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in OR
Hospital Affiliations
Providence Portland Medical Center
Providence St Vincent Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

4805 Northeast Glisan Street, Garden Level, Portland, OR 97213
Call: 503-215-6029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug, Other
Study Drug: High-dose IL-2
Study Phase: Phase 2
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: LY2157299, Capecitabine, Fluorouracil
Study Phase: Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Radiation, Biological
Study Drug: High Dose IL-2
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

3 Total Publications

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: April 06, 2022
View All 3 Publications
Similar Doctors
Advanced in Ependymoma
Dr. Steven K. Seung
Radiation Oncology
Advanced in Ependymoma
Dr. Steven K. Seung
Radiation Oncology
4805 Northeast Glisan Street, Garden Level, 
Portland, OR 
 (0.1 miles away)
503-215-6029
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Seung is a Radiation Oncologist in Portland, Oregon. Dr. Seung is rated as an Advanced provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Pleuropulmonary Blastoma, and Glioblastoma. Dr. Seung is currently accepting new patients.

Experienced in Ependymoma
Dr. Andrew Y. Kee
Radiation Oncology | Radiology
Experienced in Ependymoma
Dr. Andrew Y. Kee
Radiation Oncology | Radiology

Legacy Clinics LLC

1015 Nw 22nd Ave, 
Portland, OR 
 (4.1 miles away)
503-413-7711
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kee is a Radiation Oncologist and a Radiologist in Portland, Oregon. Dr. Kee is rated as an Advanced provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Metastatic Brain Tumor, and Lung Cancer. Dr. Kee is currently accepting new patients.

Experienced in Ependymoma
Dr. Stephen B. Bader
Radiation Oncology
Experienced in Ependymoma
Dr. Stephen B. Bader
Radiation Oncology
4805 Ne Glisan St, Garden Level, 
Portland, OR 
 (0.1 miles away)
503-215-6029
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Bader is a Radiation Oncologist in Portland, Oregon. Dr. Bader is rated as an Advanced provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Bader is currently accepting new patients.

VIEW MORE EPENDYMOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Solhjem's expertise for a condition
ConditionClose
      • Advanced
      • Familial Prostate Cancer
        Dr. Solhjem is
        Advanced
        . Learn about Familial Prostate Cancer.
        See more Familial Prostate Cancer experts
      • Lung Cancer
        Dr. Solhjem is
        Advanced
        . Learn about Lung Cancer.
        See more Lung Cancer experts
      • Muscle Invasive Bladder Cancer
        Dr. Solhjem is
        Advanced
        . Learn about Muscle Invasive Bladder Cancer.
        See more Muscle Invasive Bladder Cancer experts
      • Non-Muscle Invasive Bladder Cancer
        Dr. Solhjem is
        Advanced
        . Learn about Non-Muscle Invasive Bladder Cancer.
        See more Non-Muscle Invasive Bladder Cancer experts
      • Pallister-Hall Syndrome
        Dr. Solhjem is
        Advanced
        . Learn about Pallister-Hall Syndrome.
        See more Pallister-Hall Syndrome experts
      • Pleuropulmonary Blastoma
        Dr. Solhjem is
        Advanced
        . Learn about Pleuropulmonary Blastoma.
        See more Pleuropulmonary Blastoma experts
      View All 7 Advanced Conditions
      • Experienced
      • Acoustic Neuroma
        Dr. Solhjem is
        Experienced
        . Learn about Acoustic Neuroma.
        See more Acoustic Neuroma experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Solhjem is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Anal Cancer
        Dr. Solhjem is
        Experienced
        . Learn about Anal Cancer.
        See more Anal Cancer experts
      • Astrocytoma
        Dr. Solhjem is
        Experienced
        . Learn about Astrocytoma.
        See more Astrocytoma experts
      • Atypical Teratoid Rhabdoid Tumor (ATRT)
        Dr. Solhjem is
        Experienced
        . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
        See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
      • Brain Tumor
        Dr. Solhjem is
        Experienced
        . Learn about Brain Tumor.
        See more Brain Tumor experts
      View All 31 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.